Osimertinib-Induced Cutaneous Vasculitis Responsive to Low-Dose Dapsone Without Interruption of Anticancer Therapy: A Case Report and Review of the Literature

Osimertinib-Induced Cutaneous Vasculitis Responsive to Low-Dose Dapsone Without Interruption of Anticancer Therapy: A Case Report and Review of the Literature

A 45-year-old woman with a history of lung adenocarcinoma treated with osimertinib developed purpuric plaques and vesicles on the lower extremities after 5 months of therapy. Skin biopsy revealed leukocytoclastic vasculitis (LCV). A workup for systemic involvement was unremarkable. The patient was t...

Full description

Bibliographic Details
Main Authors: Christopher Iriarte, MD, Jonathan H. Young, MD, PhD, Michael S. Rabin, MD, Nicole R. LeBoeuf, MD, MPH
Format: Article
Language:English
Published: Elsevier 2022-11-01
Series:JTO Clinical and Research Reports
Subjects:
Cutaneous vasculitis
Osimertinib
Epidermal growth factor receptor inhibitor
Case report
Dapsone
Online Access:http://www.sciencedirect.com/science/article/pii/S2666364322001394

Internet

http://www.sciencedirect.com/science/article/pii/S2666364322001394

Similar Items